Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

Summary

The purpose of this phase II trial is to evaluate the safety and efficacy of the addition of pembrolizumab to olaparib in patients with metastatic pancreatic cancer with germline BRCA 1or BRCA 2 mutations.

General Information

NCT#: NCT04548752
Study ID: NCI-2020-06838
Trial Phase: Phase II

Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Olaparib, Pembrolizumab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search